Sfoglia per Autore
Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma.
2004 F. Farabegoli; M.A.J.A. Hermsen; C. Ceccarelli; D. Santini; M.M. Weiss; G.A. Meijer and P.J. van Diest
Green tea in human cancer
2005 F. Farabegoli
Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma
2005 F. Farabegoli; C. Ceccarelli; D. Santini; M.Taffurelli
(-)-Epigallocatechin-3-gallate down regulates estrogen receptor alpha function in MCF-7 breast carcinoma cells
2007 F. Farabegoli; C. Barbi; E. Lambertini; R. Piva
SOCS-2 expression in MCF-7 and MDA-MB-231 cells
2008 F .Farabegoli; M. Govoni
Trattamento di cellule MCF-7 resistenti al tamoxifene con (-)-epigallocatechina-3-gallato
2008 Papi A.; Orlandi M.; Bartolini G.; Farabegoli F.
XXI Convegno Annuale ABCD (Stress cellulare: sopravvivenza ed apoptosi), Atti convegno
2009 Papi A; Orlandi M; Farabegoli Fu; De Nicola G; Bagatta M; Donato A; Gennari L; Blasa M; Ninfali P.
(-)-epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line
2010 Farabegoli F.; Papi A.; Bartolini G.; Ostan R.; Orlandi M.
(-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
2011 Farabegoli F.; Papi A.; Orlandi M.
Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways.
2012 Farabegoli F.; Vettraino M.; Manerba M.; Fiume L.; Roberti M.; Di Stefano G.
Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells
2013 A. Papi; F. Farabegoli; R. Iori; M. Orlandi; G.R. De Nicola; M. Bagatta ; D. Angelino; L. Gennari; P. Ninfali
A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines.
2014 Farabegoli F; Govoni M; Ciavarella C; Orlandi M; Papi A.
Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
2016 Papi, Alessio; Govoni, Marzia; Ciavarella, Carmen; Spisni, Enzo; Orlandi, Marina; Farabegoli, Fulvia
EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion
2017 Farabegoli, Fulvia; Govoni, Marzia; Spisni, Enzo; Papi, Alessio
Betalains increase vitexin-2-O-xyloside cytotoxicity in CaCo-2 cancer cells
2017 Farabegoli, F.; Scarpa, E.S.; Frati, A.; Serafini, G.; Papi, A.; Spisni, E.; Antonini, E.; Benedetti, S.; Ninfali, P
Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors
2017 Falchi, Federico; Giacomini, Elisa; Masini, Tiziana; Boutard, Nicolas; Di Ianni, Lorenza; Manerba, Marcella; Farabegoli, Fulvia; Rossini, Lara; Robertson, Janet; Minucci, Saverio; Pallavicini, Isabella; Di Stefano, Giuseppina; Roberti, Marinella; Pellicciari, Roberto; Cavalli, Andrea
Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro
2018 Farabegoli, Fulvia*; Govoni, Marzia; Spisni, Enzo; Papi, Alessio
Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells
2019 Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano, Elisa Giacomini, Federico Falchi, Andrea Balboni, Marcella Manerba, Fulvia Farabegoli, Francesca De Franco, Janet Robertson, Saverio Minucci, Isabella Pallavicini, Giuseppina Di Stefano, Stefania Girotto, Roberto Pellicciari, and Andrea Cavalli
EGCG mediated targeting of deregulated signaling pathways and non-coding rnas in different cancers: Focus on JAK/STAT, Wnt/β-catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways
2020 Farooqi A.A.; Pinheiro M.; Granja A.; Farabegoli F.; Reis S.; Attar R.; Sabitaliyevich U.Y.; Xu B.; Ahmad A.
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
2020 Bagnolini G.; Milano D.; Manerba M.; Schipani F.; Ortega J.A.; Gioia D.; Falchi F.; Balboni A.; Farabegoli F.; De Franco F.; Robertson J.; Pellicciari R.; Pallavicini I.; Peri S.; Minucci S.; Girotto S.; Di Stefano G.; Roberti M.; Cavalli A.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma. | F. Farabegoli; M.A.J.A. Hermsen; C. Ceccarelli; D. Santini; M.M. Weiss; G.A. Meijer and P.J. van ...Diest | 2004-01-01 | MODERN PATHOLOGY | - | 1.01 Articolo in rivista | - |
| Green tea in human cancer | F. Farabegoli | 2005-01-01 | MINERVA BIOTECNOLOGICA | - | 1.01 Articolo in rivista | - |
| Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma | F. Farabegoli; C. Ceccarelli; D. Santini; M.Taffurelli | 2005-01-01 | JOURNAL OF CLINICAL PATHOLOGY | - | 1.01 Articolo in rivista | - |
| (-)-Epigallocatechin-3-gallate down regulates estrogen receptor alpha function in MCF-7 breast carcinoma cells | F. Farabegoli; C. Barbi; E. Lambertini; R. Piva | 2007-01-01 | CANCER DETECTION AND PREVENTION | - | 1.01 Articolo in rivista | - |
| SOCS-2 expression in MCF-7 and MDA-MB-231 cells | F .Farabegoli; M. Govoni | 2008-01-01 | CELLULAR ONCOLOGY | - | 4.02 Riassunto (Abstract) | - |
| Trattamento di cellule MCF-7 resistenti al tamoxifene con (-)-epigallocatechina-3-gallato | Papi A.; Orlandi M.; Bartolini G.; Farabegoli F. | 2008-01-01 | - | s.n | 4.02 Riassunto (Abstract) | - |
| XXI Convegno Annuale ABCD (Stress cellulare: sopravvivenza ed apoptosi), Atti convegno | Papi A; Orlandi M; Farabegoli Fu; De Nicola G; Bagatta M; Donato A; Gennari L; Blasa M; Ninfali P. | 2009-01-01 | - | s.n | 4.02 Riassunto (Abstract) | - |
| (-)-epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line | Farabegoli F.; Papi A.; Bartolini G.; Ostan R.; Orlandi M. | 2010-01-01 | PHYTOMEDICINE | - | 1.01 Articolo in rivista | - |
| (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. | Farabegoli F.; Papi A.; Orlandi M. | 2011-01-01 | BIOSCIENCE REPORTS | - | 1.01 Articolo in rivista | - |
| Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. | Farabegoli F.; Vettraino M.; Manerba M.; Fiume L.; Roberti M.; Di Stefano G. | 2012-01-01 | EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES | - | 1.01 Articolo in rivista | - |
| Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells | A. Papi; F. Farabegoli; R. Iori; M. Orlandi; G.R. De Nicola; M. Bagatta ; D. Angelino; L. Gennari...; P. Ninfali | 2013-01-01 | FOOD CHEMISTRY | - | 1.01 Articolo in rivista | - |
| A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines. | Farabegoli F; Govoni M; Ciavarella C; Orlandi M; Papi A. | 2014-01-01 | BIOMED RESEARCH INTERNATIONAL | - | 1.01 Articolo in rivista | BMRI2014.pdf; 853086.pdf |
| Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines | Papi, Alessio; Govoni, Marzia; Ciavarella, Carmen; Spisni, Enzo; Orlandi, Marina; Farabegoli, Fulvia | 2016-01-01 | CURRENT CANCER DRUG TARGETS | - | 1.01 Articolo in rivista | - |
| EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion | Farabegoli, Fulvia; Govoni, Marzia; Spisni, Enzo; Papi, Alessio | 2017-01-01 | BIOSCIENCE REPORTS | - | 1.01 Articolo in rivista | BSR20170168.full.pdf |
| Betalains increase vitexin-2-O-xyloside cytotoxicity in CaCo-2 cancer cells | Farabegoli, F.; Scarpa, E.S.; Frati, A.; Serafini, G.; Papi, A.; Spisni, E.; Antonini, E.; Benede...tti, S.; Ninfali, P | 2017-01-01 | FOOD CHEMISTRY | - | 1.01 Articolo in rivista | Farabegoli2017Copertina_GENERICA_UNIBO_postprint_IRIS-1.pdf |
| Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors | Falchi, Federico; Giacomini, Elisa; Masini, Tiziana; Boutard, Nicolas; Di Ianni, Lorenza; Manerba..., Marcella; Farabegoli, Fulvia; Rossini, Lara; Robertson, Janet; Minucci, Saverio; Pallavicini, Isabella; Di Stefano, Giuseppina; Roberti, Marinella; Pellicciari, Roberto; Cavalli, Andrea | 2017-01-01 | ACS CHEMICAL BIOLOGY | - | 1.01 Articolo in rivista | - |
| Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro | Farabegoli, Fulvia*; Govoni, Marzia; Spisni, Enzo; Papi, Alessio | 2018-01-01 | NUTRIENTS | - | 1.01 Articolo in rivista | nutrients-10-01141.pdf |
| Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells | Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano, Elisa Giacomini, Federico... Falchi, Andrea Balboni, Marcella Manerba, Fulvia Farabegoli, Francesca De Franco, Janet Robertson, Saverio Minucci, Isabella Pallavicini, Giuseppina Di Stefano, Stefania Girotto, Roberto Pellicciari, and Andrea Cavalli | 2019-01-01 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - | 1.01 Articolo in rivista | - |
| EGCG mediated targeting of deregulated signaling pathways and non-coding rnas in different cancers: Focus on JAK/STAT, Wnt/β-catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways | Farooqi A.A.; Pinheiro M.; Granja A.; Farabegoli F.; Reis S.; Attar R.; Sabitaliyevich U.Y.; Xu B....; Ahmad A. | 2020-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-12-00951.pdf |
| Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib | Bagnolini G.; Milano D.; Manerba M.; Schipani F.; Ortega J.A.; Gioia D.; Falchi F.; Balboni A.; F...arabegoli F.; De Franco F.; Robertson J.; Pellicciari R.; Pallavicini I.; Peri S.; Minucci S.; Girotto S.; Di Stefano G.; Roberti M.; Cavalli A. | 2020-01-01 | JOURNAL OF MEDICINAL CHEMISTRY | - | 1.01 Articolo in rivista | ASAP_acs.jmedchem.9b01526.pdf |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile